We use cookies to ensure that we give you the best experience on our website Learn more

May 15, 2019

ESOC-2019

PRE-HOSPITAL LARGE ANTERIOR VESSEL OCCLUSION RECOGNITION; AN INTER-RATER RELIABILITY STUDY

;

pre-hospital

inter-rater reliability

large anterior vessel occlusion

triage

ischemic stroke

Abstract

Abstract

thumbnail

Keywords

pre-hospital

inter-rater reliability

large anterior vessel occlusion

triage

ischemic stroke

Abstract

Background: Clinical efficacy of endovascular treatment (EVT) for ischemic stroke with large anterior vessel occlusion (LAVO) is strongly time dependent (time=brain). Therefore, several screening tools have been developed to streamline pre-hospital stroke triage to centres offering EVT. These tools, however, are largely unvalidated in a pre-hospital setting and have hitherto not been compared head-to-head for inter-rater reliability. In this study we aim to make this comparison in an experimental pre-hospital setting. Methods: Practicing emergency medical service nurses reviewed films of 10 different cases of a professional actor simulating stroke (mimic) symptoms by scoring items using a web-based application. This application collected these scores to reconstruct the following previously published screening tools: the LAMS, RACE, PASS, CPSS, G-FAST and FAST-ED. Fleiss’ Kappa in R was used to determine inter-rater reliability of each tool in a binary fashion. Results: Each of 90 EMS nurses reviewed 3 random cases. Ten cases were excluded for technical reasons resulting in a total of 260 assessments. Kappa was highest for LAMS 0.90 (95%CI 0.83-0.97) followed by FAST-ED 0.83 (95%CI 0.60-1.00), G-FAST: 0.76 (95%CI 0.51-1.00), RACE: 0.75 (95%CI 0.45-1.00), CPSS: 0.72 (95%CI 0.55-0.90) and PASS 0.58 (95%CI 0.28-0.88). Conclusion: LAMS and FAST-ED showed excellent inter-rater reliability, followed by G-FAST, RACE, CPSS and PASS. Discussion: In an experimental pre-hospital setting, a high degree of inter-rater reliability can be achieved with various LAVO screening tools. These screening tools must be validated in a real clinical setting with additional testing for predictive value of the tools for LAVO.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.